Tags

Type your tag names separated by a space and hit enter

[Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form].
Vnitr Lek 2013; 59(4):290-4VL

Abstract

Perindopril is a long acting ACE inhibitor with a 24- hour lasting effect. Its positive effect on a reduction in cardiovascular events has been confirmed in a range of large randomized clinical trials and in a wide spectrum of patients: hypertonic patients, diabetics, patients with stable ischaemic heart disease, elderly patients, or patients who have undergone a cerebrovascular accident. The extending range of various fixed combinations as well as new pharmaceutical dosage forms, including the newly introduced orodispersible tablets of perindopril, enables optimization of treatment for every patient, an increase in the patients treatment adherence, and also improvement in longterm blood pressure control with a consequent effect on reduction of morbidity and mortality.

Authors+Show Affiliations

Interni Klinika-Kardiologicka Lekarske Fakulty UP a FN Olomouc. vaclavik.j@centrum.cz

Pub Type(s)

English Abstract
Journal Article
Review

Language

cze

PubMed ID

23711055

Citation

Václavík, J. "[Perindopril in the Treatment of Hypertension and Cardiovascular Diseases: Evolution Continues With the Orodispersible Dosage Form]." Vnitrni Lekarstvi, vol. 59, no. 4, 2013, pp. 290-4.
Václavík J. [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form]. Vnitr Lek. 2013;59(4):290-4.
Václavík, J. (2013). [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form]. Vnitrni Lekarstvi, 59(4), pp. 290-4.
Václavík J. [Perindopril in the Treatment of Hypertension and Cardiovascular Diseases: Evolution Continues With the Orodispersible Dosage Form]. Vnitr Lek. 2013;59(4):290-4. PubMed PMID: 23711055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form]. A1 - Václavík,J, PY - 2013/5/29/entrez PY - 2013/5/29/pubmed PY - 2013/10/23/medline SP - 290 EP - 4 JF - Vnitrni lekarstvi JO - Vnitr Lek VL - 59 IS - 4 N2 - Perindopril is a long acting ACE inhibitor with a 24- hour lasting effect. Its positive effect on a reduction in cardiovascular events has been confirmed in a range of large randomized clinical trials and in a wide spectrum of patients: hypertonic patients, diabetics, patients with stable ischaemic heart disease, elderly patients, or patients who have undergone a cerebrovascular accident. The extending range of various fixed combinations as well as new pharmaceutical dosage forms, including the newly introduced orodispersible tablets of perindopril, enables optimization of treatment for every patient, an increase in the patients treatment adherence, and also improvement in longterm blood pressure control with a consequent effect on reduction of morbidity and mortality. SN - 0042-773X UR - https://www.unboundmedicine.com/medline/citation/23711055/[Perindopril_in_the_treatment_of_hypertension_and_cardiovascular_diseases:_evolution_continues_with_the_orodispersible_dosage_form]_ L2 - https://www.prolekare.cz/linkout/40583 DB - PRIME DP - Unbound Medicine ER -